enVVeno Medical Corporation is a medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. Chronic Venous Disease ( CVD ) is the world's most prevalent chronic disease, impacting approximately 70% of the adult population of the U.S.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$16M
▲ +10.8% YoY
Op. Margin
–
ROIC
-57.18%
▼ -5.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$13M
▲ +7.7% YoY
Op. Cash Flow (TTM)
-$13M
▲ +7.5% YoY
Net Debt
-$18M
Net Cash Position
Cash & Equiv.
$18M
Continue Research
Peers
Surgical & Medical Instruments & Apparatus · Pick stocks to compare with NVNO
EnVVeno Medical (NVNO) in three numbers
Questions about EnVVeno Medical
Is EnVVeno Medical a high-quality business?
EnVVeno Medical scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$18M, and its weakest is return on capital at -57.2%. The Quality tab shows every check against its target.
Does EnVVeno Medical (NVNO) pay a dividend?
No. EnVVeno Medical (NVNO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 27 Oct 2026 (period ending 30 Sept 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in NVNO's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing NVNO
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.